These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 26896194)

  • 41. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival.
    Smith JD; Banner NR; Hamour IM; Ozawa M; Goh A; Robinson D; Terasaki PI; Rose ML
    Am J Transplant; 2011 Feb; 11(2):312-9. PubMed ID: 21219570
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical outcomes after ABO-incompatible liver transplantation: A systematic review and meta-analysis.
    Gan K; Li Z; Bao S; Fang Y; Wang T; Jin L; Ma M; Deng L; Peng Y; Li N; Zeng Z; Huang H
    Transpl Immunol; 2021 Dec; 69():101476. PubMed ID: 34601097
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies.
    Courtwright AM; Cao S; Wood I; Mallidi HR; Kawasawa J; Moniodis A; Ng J; El-Chemaly S; Goldberg HJ
    Ann Am Thorac Soc; 2019 Sep; 16(9):1131-1137. PubMed ID: 31026404
    [No Abstract]   [Full Text] [Related]  

  • 44. Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies.
    Ixtlapale-Carmona X; Arvizu A; De-Santiago A; González-Tableros N; López M; Castelán N; Marino LA; Uribe-Uribe NO; Contreras AG; Vilatobá M; Morales-Buenrostro LE; Alberú J
    Transpl Immunol; 2018 Feb; 46():8-13. PubMed ID: 28974434
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An updated analysis of retransplantation following living donor liver transplantation in the United States: Insights from the latest UNOS database.
    Akabane M; Imaoka Y; Esquivel CO; Sasaki K
    Liver Transpl; 2024 Sep; 30(9):887-895. PubMed ID: 38727618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparing 10-yr renal outcomes in deceased donor and living donor liver transplants.
    Sandal S; Almudevar A; Parajuli S; Bose A
    Clin Transplant; 2015 Dec; 29(12):1140-7. PubMed ID: 26383173
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of Recipient Age at Liver Transplantation on Prevalence of Post-Transplant Donor-Specific HLA Antibody.
    Tokodai K; Miyagi S; Nakanishi C; Hara Y; Nakanishi W; Unno M; Kamei T
    Ann Transplant; 2017 Jun; 22():333-337. PubMed ID: 28572563
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Donor-specific anti-HLA antibodies are not associated with nonanastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation.
    den Dulk AC; Shi X; Verhoeven CJ; Dubbeld J; Claas FHJ; Wolterbeek R; Brand-Schaaf SH; Verspaget HW; Sarasqueta AF; van der Laan LJW; Metselaar HJ; van Hoek B; Kwekkeboom J; Roelen DL
    Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29193362
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of pharmacokinetics of mycophenolic acid and its metabolites between living donor liver transplant recipients and deceased donor liver transplant recipients.
    Shen B; Chen B; Zhang W; Mao H; Shen C; Deng X; Zhan X; Chen H
    Liver Transpl; 2009 Nov; 15(11):1473-80. PubMed ID: 19877254
    [TBL] [Abstract][Full Text] [Related]  

  • 50. When Living Donor Liver Allografts Fail: Exploring the Outcomes of Retransplantation Using Deceased Donors.
    Bittermann T; Shaked A; Goldberg DS
    Am J Transplant; 2017 Apr; 17(4):1097-1102. PubMed ID: 27596956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation.
    Fisher RA; Kulik LM; Freise CE; Lok AS; Shearon TH; Brown RS; Ghobrial RM; Fair JH; Olthoff KM; Kam I; Berg CL;
    Am J Transplant; 2007 Jun; 7(6):1601-8. PubMed ID: 17511683
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post-renal transplantation.
    Hassan S; Regan F; Brown C; Harmer A; Anderson N; Beckwith H; Roufosse CA; Santos-Nunez E; Brookes P; Taube D; Willicombe M
    Am J Transplant; 2019 Jun; 19(6):1720-1729. PubMed ID: 30582278
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Significance of Pretransplant Donor-Specific Antibodies in the Setting of Negative Cell-Based Flow Cytometry Crossmatching in Kidney Transplant Recipients.
    Adebiyi OO; Gralla J; Klem P; Freed B; Davis S; Wiseman AC; Cooper JE
    Am J Transplant; 2016 Dec; 16(12):3458-3467. PubMed ID: 27140940
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence and Impact of Reformed and De Novo Anti-HLA Donor-Specific Antibodies in Liver Transplantation.
    Papachristou M; Fylaktou A; Daoudaki M; Cholongitas E; Karampatakis T; Anastasiou A; Chatzika G; Makrovasili F; Vagiotas L; Karakasi K; Fouzas I
    Transplant Proc; 2019 Mar; 51(2):424-428. PubMed ID: 30879557
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
    Tran A; Fixler D; Huang R; Meza T; Lacelle C; Das BB
    J Heart Lung Transplant; 2016 Jan; 35(1):87-91. PubMed ID: 26422083
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A report of the epidemiology of de novo donor-specific anti-HLA antibodies (DSA) in "low-risk" renal transplant recipients.
    Rebellato LM; Everly MJ; Haisch CE; Ozawa M; Briley KP; Parker K; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC
    Clin Transpl; 2011; ():337-40. PubMed ID: 22755428
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
    Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
    Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
    Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
    Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients.
    Del Bello A; Congy-Jolivet N; Muscari F; Lavayssière L; Esposito L; Cardeau-Desangles I; Guitard J; Dörr G; Suc B; Duffas JP; Alric L; Bureau C; Danjoux M; Guilbeau-Frugier C; Blancher A; Rostaing L; Kamar N
    Am J Transplant; 2014 Apr; 14(4):867-75. PubMed ID: 24580771
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.
    Zhang Q; Hickey M; Drogalis-Kim D; Zheng Y; Gjertson D; Cadeiras M; Khuu T; Baas AS; Depasquale EC; Halnon NJ; Perens G; Alejos J; Cruz D; Ali N; Shemin R; Kwon M; Fishbein MC; Ardehali A; Deng M; Reed EF
    Transplantation; 2018 Oct; 102(10):e431-e438. PubMed ID: 29916988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.